423.93 USD
-22.12 (-4.96%)
At close: Feb 11, 2026
423.93 USD
0 (0%)
After Hours: 2/11/2026, 4:10:09 PM
Taking everything into account, MEDP scores 6 out of 10 in our fundamental rating. MEDP was compared to 58 industry peers in the Life Sciences Tools & Services industry. MEDP gets an excellent profitability rating and is at the same time showing great financial health properties. MEDP has a decent growth rate and is not valued too expensively. With these ratings, MEDP could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
- In the past year MEDP was profitable.
- MEDP had a positive operating cash flow in the past year.
- MEDP had positive earnings in 4 of the past 5 years.
- Of the past 5 years MEDP 4 years had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 24.70%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 147.46%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 91.45%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for MEDP is significantly above the industry average of 13.21%.
- The last Return On Invested Capital (91.45%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROIC | 91.45% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
- MEDP has a Profit Margin of 18.36%. This is amongst the best in the industry. MEDP outperforms 91.38% of its industry peers.
- In the last couple of years the Profit Margin of MEDP has grown nicely.
- The Operating Margin of MEDP (21.50%) is better than 89.66% of its industry peers.
- MEDP's Operating Margin has improved in the last couple of years.
- MEDP's Gross Margin of 31.11% is on the low side compared to the rest of the industry. MEDP is outperformed by 70.69% of its industry peers.
- MEDP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
- MEDP has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- MEDP has an Altman-Z score of 6.62. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
- MEDP's Altman-Z score of 6.62 is amongst the best of the industry. MEDP outperforms 87.93% of its industry peers.
- MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.62 |
ROIC/WACC8.28
WACC11.04%
2.3 Liquidity
- A Current Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
- The Current ratio of MEDP (0.57) is worse than 94.83% of its industry peers.
- MEDP has a Quick Ratio of 0.57. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.57, MEDP is not doing good in the industry: 93.10% of the companies in the same industry are doing better.
- The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 21.14% over the past year.
- Measured over the past years, MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 31.30% on average per year.
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.03%
3.2 Future
- Based on estimates for the next years, MEDP will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.29% on average per year.
- The Revenue is expected to grow by 10.47% on average over the next years. This is quite good.
EPS Next Y9.87%
EPS Next 2Y10.52%
EPS Next 3Y10.19%
EPS Next 5Y10.29%
Revenue Next Year11.99%
Revenue Next 2Y10.2%
Revenue Next 3Y11.36%
Revenue Next 5Y10.47%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- MEDP is valuated quite expensively with a Price/Earnings ratio of 27.71.
- Based on the Price/Earnings ratio, MEDP is valued a bit cheaper than the industry average as 63.79% of the companies are valued more expensively.
- MEDP is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.03, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 25.22, MEDP can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, MEDP is valued a bit cheaper than the industry average as 70.69% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 27.97, MEDP is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.71 | ||
| Fwd PE | 25.22 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MEDP is valued a bit cheaper than 63.79% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of MEDP indicates a rather cheap valuation: MEDP is cheaper than 86.21% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.65 | ||
| EV/EBITDA | 22.93 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of MEDP may justify a higher PE ratio.
PEG (NY)2.81
PEG (5Y)0.89
EPS Next 2Y10.52%
EPS Next 3Y10.19%
5. Dividend
5.1 Amount
- No dividends for MEDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
423.93
-22.12 (-4.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-09 2026-02-09/amc
Earnings (Next)04-20 2026-04-20/amc
Inst Owners87.1%
Inst Owner Change-0.63%
Ins Owners0.44%
Ins Owner Change-6.05%
Market Cap11.94B
Revenue(TTM)N/A
Net Income(TTM)433.00M
Analysts52.22
Price Target557.47 (31.5%)
Short Float %6.04%
Short Ratio5.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)1.27%
PT rev (3m)7.24%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)-0.09%
EPS NY rev (1m)0%
EPS NY rev (3m)5.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.71 | ||
| Fwd PE | 25.22 | ||
| P/S | 5.06 | ||
| P/FCF | 17.65 | ||
| P/OCF | 16.79 | ||
| P/B | 40.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | 22.93 |
EPS(TTM)15.3
EY3.61%
EPS(NY)16.81
Fwd EY3.97%
FCF(TTM)24.02
FCFY5.67%
OCF(TTM)25.25
OCFY5.96%
SpS83.72
BVpS10.42
TBVpS-14.29
PEG (NY)2.81
PEG (5Y)0.89
Graham Number59.9
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROCE | 108.09% | ||
| ROIC | 91.45% | ||
| ROICexc | 233.48% | ||
| ROICexgc | N/A | ||
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% | ||
| FCFM | 28.7% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.93% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.81% | ||
| Profit Quality | 156.3% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 6.62 |
F-Score8
WACC11.04%
ROIC/WACC8.28
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
EPS Next Y9.87%
EPS Next 2Y10.52%
EPS Next 3Y10.19%
EPS Next 5Y10.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.03%
Revenue Next Year11.99%
Revenue Next 2Y10.2%
Revenue Next 3Y11.36%
Revenue Next 5Y10.47%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year28.4%
EBIT Next 3Y15.87%
EBIT Next 5Y14.69%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 6 / 10 to MEDP.
Can you provide the valuation status for MEDPACE HOLDINGS INC?
ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
What is the profitability of MEDP stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 8 / 10.
What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?
The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 27.71 and the Price/Book (PB) ratio is 40.67.
How financially healthy is MEDPACE HOLDINGS INC?
The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 7 / 10.